- Home
- HIND vs SNGX Comparison
HIND vs SNGX Comparison
Compare HIND & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIND
- SNGX
- Stock Information
- Founded
- HIND N/A
- SNGX 1987
- Country
- HIND United States
- SNGX United States
- Employees
- HIND N/A
- SNGX N/A
- Industry
- HIND
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- HIND
- SNGX Health Care
- Exchange
- HIND Nasdaq
- SNGX Nasdaq
- Market Cap
- HIND 10.3M
- SNGX 10.1M
- IPO Year
- HIND 2016
- SNGX 1987
- Fundamental
- Price
- HIND $7.95
- SNGX $2.86
- Analyst Decision
- HIND
- SNGX Strong Buy
- Analyst Count
- HIND 0
- SNGX 1
- Target Price
- HIND N/A
- SNGX $6.00
- AVG Volume (30 Days)
- HIND N/A
- SNGX 10.2M
- Earning Date
- HIND N/A
- SNGX 11-07-2025
- Dividend Yield
- HIND N/A
- SNGX N/A
- EPS Growth
- HIND N/A
- SNGX N/A
- EPS
- HIND N/A
- SNGX N/A
- Revenue
- HIND N/A
- SNGX N/A
- Revenue This Year
- HIND N/A
- SNGX N/A
- Revenue Next Year
- HIND N/A
- SNGX N/A
- P/E Ratio
- HIND N/A
- SNGX N/A
- Revenue Growth
- HIND N/A
- SNGX N/A
- 52 Week Low
- HIND N/A
- SNGX $1.09
- 52 Week High
- HIND N/A
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- HIND N/A
- SNGX 49.77
- Support Level
- HIND N/A
- SNGX $2.72
- Resistance Level
- HIND N/A
- SNGX $3.11
- Average True Range (ATR)
- HIND 0.00
- SNGX 0.49
- MACD
- HIND 0.00
- SNGX -0.10
- Stochastic Oscillator
- HIND 0.00
- SNGX 3.99
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).